The hormone receptor-positive (HR+) subtype expresses > 1% ER and/or PR, while the HER2-positive (HER2+) subtype demonstrates the abnormal amplification of the ERBB2 gene and subsequent overexpression of the HER2 protein, whereas the triple-negative breast cancer (TNBC) subtype lacks the expression of all three markers [3,4]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.